
After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ:MRNA) is on the lookout for the next big catalyst to boost its rangebound stock.
The Moderna Analyst: BofA Securities analyst Geoff Meacham reiterated a Neutral rating on Moderna shares and increased the price target from $170 to $180.